Stage 0


Not all DCIS patients will benefit from the addition of radiation therapy to their treatment. Genomic Health's Oncotype DX Breast Cancer Assay for DCIS patients provides a DCIS score from which breast cancer doctors and their patients can determine the appropriate personalized treatment plan.

Team Xplore's picture

In this video, Dr. Jay K. Harness describes the typical treatment strategy for low-grade ductal carcinoma in situ, or DCIS. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.


Amy, a breast cancer survivor, describes her experience using Genomic Health's Oncotype DX DCIS Breast Cancer Score to personalize her treatment options. Share this video with your loved ones to help empower other women facing a DCIS (ductal carcinoma in situ) breast cancer diagnosis to ask for personalized treatment. For more information, please visit:


Patients diagnosed with DCIS breast cancer can obtain an Oncotype DX DCIS Score, which is covered by Medicare, but reimbursement for private payers can vary. Genomic Health Senior Director of Pathology Dr. Rick Baehner explains that Genomic Health will work with DCIS breast cancer patients and their insurance companies to arrange coverage.


Ductal carcinoma in situ is considered to be Stage 0 breast cancer. It's also known as DCIS. What is that? It's a localized breast cancer that has not yet invaded the tissues surrounding the localized lesion.

Some medical experts believe this cancer does not need treatment. Others disagree. You might ask yourself, "How can anyone suggest I not get treatment for a confirmed diagnosis of breast cancer?" Watch the video to learn more.

To learn more about how medical malpractice cases work in New York, I encourage you to explore my educational website, If you have legal questions, I urge you to pick up the phone and call me since I can answer your legal questions at 516-487-8207 or by e-mail at I welcome your call.

The Law Office of Gerald Oginski, LLC
25 Great Neck Rd., Suite 4
Great Neck, NY 1021


In this video from the National Comprehensive Cancer Network (NCCN), breast cancer surgeon Stephen Edge, MD, Chair of Breast and Soft Tissue Surgery at Roswell Park Cancer Institute, explains how ductal carcinoma in situ (DCIS) is different from invasive breast cancer and why women with ductal carcinoma in situ usually do not get chemotherapy. The NCCN is a not-for-profit alliance of 21 leading cancer centers—including Roswell Park Cancer Institute—dedicated to improving care for cancer patients. You can find more information on breast cancer in the NCCN Guidelines for Patients with Breast Cancer, available at These guidelines, part of the NCCN Guidelines for Patients series, discuss most types of breast cancer along with treatment options.


Every year thousands of women are diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS) after having a routine mammogram. We interviewed 35 women about their experiences of DCIS found through routine breast screening. This video contains a series of excerpts from those interviews. To see more visit


Web Chat with the Expert series on Advances in Treatment Decision Making for Patients with Ductal Carcinoma in Situ (DCIS). Question and Answer session.